Your browser doesn't support javascript.
loading
Efficacy of Platelet-Rich Plasma in the Treatment of Diabetic Foot Ulcer.
Azam, Muhammad Saim; Azad, Muhammad Hassan; Arsalan, Muhammad; Malik, Ahmed; Ashraf, Raza; Javed, Hamza.
Afiliação
  • Azam MS; General Surgery, CDA (Capital Development Authority) Hospital, Islamabad, PAK.
  • Azad MH; General Surgery, CDA (Capital Development Authority) Hospital, Islamabad, PAK.
  • Arsalan M; General Surgery, DHQ (District Headquarter) Hospital, Bahawalnagar, PAK.
  • Malik A; Renal Transplant, St George's Hospital, London, GBR.
  • Ashraf R; General Surgery, Shifa International Hospital, Islamabad, PAK.
  • Javed H; Radiology, Ayub Teaching Hospital, Abbottabad, PAK.
Cureus ; 16(5): e60934, 2024 May.
Article em En | MEDLINE | ID: mdl-38910752
ABSTRACT
Introduction Diabetic foot complications leading to limb amputations pose a global health concern. Platelet-rich plasma (PRP) gel has emerged as a promising method for ulcer healing, leveraging the growth factors provided by autologous PRP to enhance tissue healing. Therefore, we aimed to assess the frequency of the success of PRP therapy in the treatment of non-healing diabetic foot ulcers. Methods This quasi-experimental study, conducted in Lahore, Pakistan, from April 2021 to October 2022, enrolled 80 eligible individuals with non-responsive diabetic foot ulcers using a consecutive sampling technique. Inclusion criteria involved patients of both genders, aged 45-75 years, with unhealed diabetic foot ulcers, and exclusion criteria considered factors such as recurrent ulcers at the same site, smoking, and immunosuppressive or anticoagulant drug therapy. Baseline demographic details, ulcer measurements using a scale, and AutoCAD (Autodesk, Inc., San Francisco, California, United States)-assisted quantification of ulcer base were recorded. Autologous PRP injections were administered following strict aseptic protocols, with dressing changes and assessments performed at specified intervals over four weeks. Treatment success, defined as >90% healing after four weeks, was the primary outcome. Data analysis utilized IBM SPSS Statistics for Windows, Version 26.0 (Released 2019; IBM Corp., Armonk, New York, United States), employing post-stratification chi-square and t-tests where appropriate for significant differences. Results The mean age of the patients was 60.40 ± 9.72 years, the mean duration of diabetes was 9.48 ± 2.21 years, and the mean ulcer duration was 11.41 ± 1.63 months. The treatment success rate was 63.7%. Age, gender, and disease duration showed no significant impact on treatment success. However, patients with a normal BMI and shorter ulcer duration exhibited a significantly higher success rate (p <0.001 and p = 0.002, respectively). Conclusions This study reaffirms the efficacy of PRP in treating non-healing diabetic foot ulcers, aligning with previous research. Despite a slightly lower success rate compared to literature reports, PRP remains a promising agent for managing diabetic foot ulcers.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cureus Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cureus Ano de publicação: 2024 Tipo de documento: Article